

09/705,5/9

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-41 (canceled)

42. (previously presented) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising administering an anti-ErbB2 antibody and Vinorelbine to a patient in amounts to kill or inhibit growth of tumor cells in the patient, wherein the tumor or cancer is selected from the group consisting of a liver tumor, colorectal tumor, prostate tumor, pancreatic tumor, vulval tumor, thyroid tumor, hepatic tumor, sarcoma, glioblastoma, head and neck tumor, leukemia and lymphoid malignancy.

43. (Canceled)

44. (previously presented) The method of claim 42 wherein the tumor or cancer is a colorectal tumor.

45-54 (Canceled)

55. (previously presented) The method of claim 42 wherein the anti-ErbB2 antibody binds to an ErbB2 epitope bound by antibody 4D5 (ATCC CRL 10463).

56.-62. (Canceled)

63. (previously presented) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising a first therapeutic regimen comprising administering an anti-ErbB2

09/705,579

antibody to a patient in an amount to kill or inhibit growth of tumor cells in the patient and a second therapeutic regimen comprising administering Vinorelbine in an amount to inhibit growth of tumor cells in the patient.

64. (Canceled)

65. (previously presented) The method of claim 63 wherein the anti-ErbB2 antibody binds to an ErbB2 epitope bound by antibody 4D5 (ATCC CRL 10463).

66.-68. (Canceled)

69. (New) A method of treating breast cancer characterized by overexpression or activation of ErbB2 comprising administering to a patient an anti-ErbB2 antibody which binds to an ErbB2 epitope bound by antibody 4D5 (ATCC CRL 10463), and Vinorelbine, each in amounts effective to treat the breast cancer.